Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051171 | 0.98 | RAB9A (0.69) | CYP2C9CYP2C19POLBKDM4ERAB9A | |
| SCHEMBL420582 | 0.98 | RAB9A (0.69) | CYP2C9CYP2C19POLBKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL7128759 | 0.98 | POLB (0.72) | CYP2C9CYP2C19POLBKDM4ERAB9A | |
| SCHEMBL570715 | 0.96 | CYP2C9 (0.71) | CYP2C9CYP2C19POLBKDM4ERAB9A | |
| SCHEMBL10729724 | 0.92 | KDM4E (0.77) | CYP2C9CYP2C19POLBKDM4EKMT2A | |
| SCHEMBL2897923 | 0.92 | KDM4E (0.77) | CYP2C9CYP2C19POLBKDM4EKMT2A | |
| Trifluoroacetic Acid SCHEMBL18050103 | 0.90 | KMT2A (0.59) | CYP2C9CYP2C19POLBKDM4ERAB9A | |
| SCHEMBL20236166 | 0.86 | KDM4E (0.70) | CYP2C9CYP2C19POLBKDM4EKMT2A | |
| SCHEMBL11181938 | 0.85 | GAA (0.58) | CYP2C9CYP2C19POLBKDM4ERAB9A | |
| SCHEMBL311835 | 0.85 | SMN1; SMN2 (0.66) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | claimed |
| CN-117383994-A | Preparation method of asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20230295236-A1 | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-09-21 | — | — | US | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
| EP-3277677-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2018-02-07 | — | — | EP | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5283362-A | Reacting with an amine, terminating the reaction before the formation of by-product | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1994-02-01 | — | — | US | disclosed |
| US-4128643-A | 4-Quinazolinyl-guanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-12-05 | — | — | US | disclosed |
| US-4065291-A | Herbicidal 1-(2-hydroxymethylpyrrolidinyl) carboxanilides | CHEVRON RESEARCH COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-3778247-A | METHOD FOR REGULATING PLANT GROWTH | RICERCA, INC., 7528 AUBURN ROAD, CONCORD TOWNSHIP, PAINESVILLE, OHIO 44077 | 1973-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295236-A1 | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | TLR4, TLR3, TLR2 | CYP2C9 4080/4885CYP2C19 3471/4885POLB 3588/4885 |
| US-11465989-B2 | Guanidine compounds and use thereof | PC, TFAM, PCK2 | CYP2C9 1744/4885CYP2C19 2070/4885POLB 264/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP2C9 4775/4885CYP2C19 4820/4885POLB 2779/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP2C9 4775/4885CYP2C19 4820/4885POLB 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.